Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia

Abstract Introduction Plasma markers have been reported to be associated with brain amyloid burden, tau pathology, or neurodegeneration. We aimed to evaluate whether plasma biomarker profiles could predict Alzheimer's disease (AD) pathology and clinical progression in older adults without demen...

Full description

Bibliographic Details
Main Authors:	Xue‐Ning Shen, Jie‐Qiong Li, Hui‐Fu Wang, Hong‐Qi Li, Yu‐Yuan Huang, Yu‐Xiang Yang, Lan Tan, Qiang Dong, Jin‐Tai Yu, Alzheimer's Disease Neuroimaging Initiative
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:	Alzheimer's disease amyloid beta mild cognitive impairment neurofilament light plasma p‐tau181
Online Access:	https://doi.org/10.1002/dad2.12104

Similar Items

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
by: Yu Guo, et al.
Published: (2021-05-01)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
by: Christopher Clark, et al.
Published: (2021-03-01)

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study
by: Yan-Li Wang, et al.
Published: (2021-09-01)

Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease
by: Feng Xing, et al.
Published: (2021-06-01)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
by: Lauren E. McCollum, et al.
Published: (2021-01-01)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01)

Levels of Cortisol in CSF Are Associated With SNAP-25 and Tau Pathology but Not Amyloid-β
by: Qing Wang, et al.
Published: (2018-11-01)

Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease
by: Omar A. Halawa, et al.
Published: (2019-01-01)

Review Paper: Tau Pathology of Alzheimer Disease: Possible Role of Sleep Deprivation
by: Nahid Ahmadian, et al.
Published: (2018-09-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
by: Harutsugu Tatebe, et al.
Published: (2017-09-01)

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
by: Anna Zettergren, et al.
Published: (2021-01-01)

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg
by: Pawel Obrocki, et al.
Published: (2020-02-01)

Pathological correlates of impaired self-awareness of memory function in Alzheimer’s disease
by: Geoffroy Gagliardi, et al.
Published: (2021-06-01)

Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)

Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer's Disease
by: Ryszard Pluta, et al.
Published: (2021-02-01)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
by: Xulong Ding, et al.
Published: (2021-03-01)

Season of birth and vulnerability to the pathology of Alzheimer's disease: an in vivo positron emission tomography study
by: Alzheimer's Disease Neuroimaging Initiative, et al.
Published: (2022)

Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia
by: Meng-Shan Tan, et al.
Published: (2020-05-01)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
by: Cécile Tissot, et al.
Published: (2021-03-01)

Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer’s dementia: a comparison of methods
by: Arnd Sörensen, et al.
Published: (2020-11-01)

Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration
by: Meng-Shan Tan, et al.
Published: (2021-01-01)

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
by: Ting-Bin Chen, et al.
Published: (2021-10-01)

Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
by: Vanessa de Jesus R. de Paula, et al.

Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study
by: Filippo Baldacci, et al.
Published: (2020-11-01)

Inhibiteurs et modèles moléculaires de fibres amyloïdes ° et tau impliquées dans la maladie d'Alzheimer : conception, synthèse et caractérisation
by: Dufour, Emilie
Published: (2013)

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology
by: Noemi Esteras, et al.
Published: (2020-09-01)

Tau and neurofilaments in a family with frontotemporal dementia unlinked to chromosome 17q21–22
by: Armand Savioz, et al.
Published: (2003-02-01)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
by: Fuyuki Kametani, et al.
Published: (2018-01-01)

Staging of amyloid β, t‐tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses
by: Evan Fletcher, et al.
Published: (2018-01-01)

Participation of Amyloid and Tau Protein in Neuronal Death and Neurodegeneration after Brain Ischemia
by: Ryszard Pluta, et al.
Published: (2020-06-01)

Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice
by: Sarah Houben, et al.
Published: (2020-07-01)

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia
by: Lutz Frölich, et al.
Published: (2017-10-01)

In vivo network models identify sex differences in the spread of tau pathology across the brain
by: Sepideh Shokouhi, et al.
Published: (2020-01-01)

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
by: Dong-Yu Fan, et al.
Published: (2021-01-01)

Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy
by: Yingjian You, et al.
Published: (2019-02-01)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
by: Jurre den Haan, et al.
Published: (2018-12-01)

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
by: Danni Li, et al.
Published: (2019-12-01)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
by: Umesh Gangishetti, et al.
Published: (2018-09-01)

Cannot write session to /tmp/vufind_sessions/sess_a9q5uokvbfcjb19dvv37g7r7so